Company Overview and News

20
Tracking Alex Roepers' Atlantic Investment Management Portfolio - Q2 2018 Update

2018-08-20 seekingalpha - 2
Atlantic Investment Management’s 13F portfolio value decreased from $727M to $645M. The number of positions decreased from 18 to 16.
LKSD ARRS TGI LEN CLZNF LEN.B LKSD.WI TEN NCR HUN IP OSK EMN AVTCQ ADT CLZNY OI INPAP COMM NAV SCS AVT BDC DBD WRK

 
COMM / CommScope Holding Company, Inc. 8-K (Current Report)

2018-08-13 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
COMM

 
COMM / CommScope Holding Company, Inc. / Capital Research Global Investors - SC 13G/A (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CommScope Holding Company, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 20337X109 (CUSIP Number) July 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
COMM

 
COMM / CommScope Holding Company, Inc. / Capital Research Global Investors - SC 13G/A (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CommScope Holding Company, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 20337X109 (CUSIP Number) July 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
COMM

12
Top Analyst Upgrades and Downgrades: Applied Materials, Barrick Gold, Comcast, GoDaddy, Intel, PG&E, Qualcomm, Sirius XM and More

2018-08-06 247wallst
Stocks were indicated to open lower by a tiny margin on Monday, after the indications were for a positive open earlier in the morning. Investors have had less success buying the all the stock market dips in 2018 than in prior years. Many investors also are reconsidering how they want their investments positioned ahead of the midterm elections and with international trade concerns.
PCG FMX CCV DXCM DVN CCZ AMAT MS INTC CMCSK ABX CWST ABX CMCSA FMXUF COMM CCV.CL HMSY TRI GDDY QCOM

3
CommScope (COMM) Q2 Earnings and Revenues Beat Estimates

2018-08-01 zacks
CommScope Holding Company, Inc. (COMM - Free Report) reported healthy results in the second quarter of 2018, wherein both the top line and bottom line beat the respective Zacks Consensus Estimate. Net Income On a GAAP basis, quarterly net income was $65.9 million or 34 cents per share compared with $55.5 million or 28 cents per share in the year-ago quarter, primarily driven by higher North American sales volumes and cost-reduction initiatives.
MSI CMTL MU COMM

 
CommScope Holding (COMM) Q2 2018 Results - Earnings Call Transcript

2018-07-31 seekingalpha
Good day, ladies and gentlemen, and welcome to the CommScope Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time.
DB COMM MS

 
CommScope Holding Company Inc. 2018 Q2 - Results - Earnings Call Slides

2018-07-31 seekingalpha
The following slide deck was published by CommScope Holding Company Inc. in conjunction with their 2018 Q2 earnings call.
COMM

 
COMM / CommScope Holding Company, Inc. 8-K (Current Report)

2018-07-31 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
COMM

 
COMM / CommScope Holding Company, Inc. 10-Q (Quarterly Report)

2018-07-31 sec.gov
comm-10q_20180630.htm UNITED STATES
COMM

13
Telecom Stocks Earnings Roster for Jul 31: HRS, COMM & More

2018-07-30 zacks - 1
The earnings season is past the halfway mark with 265 S&P 500 members having reported results till Jul 27, 2018. Sustained momentum reinforces expectations that second-quarter 2018 is likely to replicate the performance of the prior quarter, which proved to be one of the strongest in the past seven years. Total earnings for the S&P 500 companies that have already reported are up 23.6% year over year on 10.
ALGN IBN IRDDA COMM SAH I IRIIZ ICICIBANK 532174 IRDMB HRS SEND IRDM

115
Oakmark Equity And Income Fund: Second Quarter 2018

2018-07-11 seekingalpha
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM DOV.WI NOV TEL CVS FNF BAC CHTR APY.WI FNFV DOV GM ORCL LBRDB BAC C AAL BHGE COMM MA ARNC TWC LBRDK BHI CGBBW OCLCF JLL LBRDA FL APY UNH

4
Weekly Insider Trading, July 1

2018-07-02 seekingalpha
CommScope - also a setup where insiders are shifting from selling to buying, looking for a mean reversion.
CWH DFRG COMM RTN HWKN

70
Boardwalk Pipeline Partners downgraded to neutral from overweight at J.P. Morgan

2018-06-27 marketwatch
A tax change may prompt the conglomerate to buy out minority unit holders of Boardwalk Pipeline. Some are worried about the price.
LGCYP LGCYO CQP LNG COMM BWP L BPL EXAS PDCO AM BRK.A SRLP TCP LGCY

45
Zacks Industry Outlook Highlights: ADTRAN, CommScope and Superconductor Technologies

2018-06-21 zacks - 1
Chicago, IL – June 21, 2018 – Today, Zacks Equity Research discusses Communication Infrastructure, including ADTRAN, Inc. (ADTN - Free Report) , CommScope Holding Company, Inc. (COMM - Free Report) and Superconductor Technologies Inc. (SCON - Free Report) .
LOPE ALGN SCVL ADTN COMM SCON

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to COMM / CommScope Holding Company, Inc. on message board site Silicon Investor.

Qualcomm Moderated Thread - please read rules before posting Qualcomm Moderated Thread - please read rules before posting Qualcomm Moderated Thread - please read rules before posting Verizon Communications (VZ) Verizon Communications (VZ) Verizon Communications (VZ)
The New Qualcomm - write what you like thread. The New Qualcomm - write what you like thread. The New Qualcomm - write what you like thread. Globalstar Telecommunications Limited GSAT Globalstar Telecommunications Limited GSAT Globalstar Telecommunications Limited GSAT
General market lab and commentary General market lab and commentary General market lab and commentary Sequans Communications Sequans Communications Sequans Communications
The New QUALCOMM - Coming Into Buy Range The New QUALCOMM - Coming Into Buy Range The New QUALCOMM - Coming Into Buy Range GUMM - Eliminate the Common Cold GUMM - Eliminate the Common Cold GUMM - Eliminate the Common Cold
Authors u0026 Books u0026 Comments Authors u0026 Books u0026 Comments Authors u0026 Books u0026 Comments NXPI after Qualcomm failed bid NXPI after Qualcomm failed bid NXPI after Qualcomm failed bid
CUSIP: 20337X109